Welcome to our dedicated page for Poseida Therapeutics news (Ticker: PSTX), a resource for investors and traders seeking the latest updates and insights on Poseida Therapeutics stock.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) is a clinical-stage biopharmaceutical company that specializes in developing innovative cell and gene therapies aimed at curing certain cancers and rare diseases. The company's core focus is on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with unmet medical needs. Poseida's pipeline includes autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates, initially targeting hematological malignancies and solid tumors.
Poseida boasts best-in-class genome engineering capabilities, utilizing proprietary tools like the piggyBac™ DNA modification system, nextGEN™ CRISPR, XTN™ TALEN, and the footprint-free™ gene editing system. These tools are virus-free and offer surgical precision in gene editing, enabling the development of highly effective therapies.
Recent achievements include significant advancements in the company's lead program, P-BCMA-ALLO1, a novel BCMA-targeted allogeneic CAR-T therapy for treating relapsed/refractory multiple myeloma (RRMM). The FDA recently granted Orphan Drug Designation for P-BCMA-ALLO1, underscoring its potential to meet high unmet medical needs. Poseida is investigating this therapy in collaboration with Roche, with promising preliminary data presented at major scientific conferences.
In addition to its focus on cancer, Poseida is also advancing genetic medicines for rare diseases. The company has highlighted progress in its gene therapy pipeline, especially for conditions like Hereditary Angioedema and Hemophilia A. These programs employ fully non-viral approaches, leveraging Poseida's advanced genetic engineering and delivery platforms.
Poseida has formed strategic collaborations with industry giants like Janssen and Roche, enhancing its capacity to bring innovative therapies to market. The company also recently entered into a research collaboration with Xyphos Biosciences, a subsidiary of Astellas, to develop novel convertibleCAR® programs targeting solid tumors.
Financially, Poseida reported revenues of $28.1 million for Q1 2024, a substantial increase from the previous year, primarily driven by collaborations with Astellas and Roche. With a strong cash position and additional funding from strategic partnerships, Poseida is well-positioned to advance its pipeline and achieve key milestones in 2024 and beyond.
Learn more about Poseida Therapeutics and its groundbreaking work by visiting www.poseida.com and connecting with the company on X and LinkedIn.
Poseida Therapeutics (Nasdaq: PSTX) has announced new executive leadership appointments effective immediately. Johanna Mylet is the new Chief Financial Officer, Devon Shedlock becomes Chief Scientific Officer for Cell Therapies, Kristin Martin takes on the role of Chief People and Administration Officer, and Lisa Portale is now Senior Vice President for Regulatory Affairs. The company aims to enhance its capabilities in cell and gene therapy following a strategic collaboration with Takeda. These changes support Poseida's mission to develop transformative therapies for cancer and rare diseases.
Poseida Therapeutics (Nasdaq: PSTX) announced a collaboration and exclusive license agreement with Takeda Pharmaceutical Company to develop up to eight gene therapies using Poseida's innovative genetic engineering technologies. The initial focus will be on non-viral in vivo gene therapy programs, including a Hemophilia A program. Poseida will receive an upfront payment of $45 million, with potential additional payments exceeding $2.7 billion, depending on milestone achievements. The partnership aims to provide novel therapies for rare genetic diseases and enhance Poseida's development capabilities.
Poseida Therapeutics (PSTX) announced two virtual poster presentations at the Society for Immunotherapy of Cancer's 36th Annual Meeting, scheduled for November 10-14, 2021. Presentations will cover:
- Memory Phenotype in Allogeneic Anti-BCMA CAR-T Cell Therapy (P-BCMA-ALLO1), presented by Hubert Tseng, Ph.D., on November 12, 2021.
- P-MUC1C-ALLO1: A Fully Allogeneic Stem Cell Memory T Cell CAR-T Therapy, presented by Yan Zhang, Ph.D., also on November 12, 2021.
Details will be available on the SITC website on November 9, 2021.
Poseida Therapeutics (Nasdaq: PSTX), a clinical-stage biopharmaceutical company, announced its participation in upcoming virtual investor conferences. The H. C. Wainwright 23rd Annual Global Investment Conference will feature an on-demand session starting September 13, 2021, at 7:00 am ET. Additionally, the Cantor Fitzgerald Global Healthcare Conference is scheduled for September 27, 2021, at 8:40 am ET. Webcasts will be available on Poseida's website, with replays accessible for 30 days. Poseida aims to develop innovative cell and gene therapeutics using its proprietary genetic engineering platforms.
Poseida Therapeutics (PSTX) announced preliminary results from its Phase 1 trial of P-PSMA-101 for treating metastatic castrate-resistant prostate cancer (mCRPC). The trial showed that five out of nine patients had measurable declines in PSA levels, with one patient achieving complete tumor elimination. Notably, the treatment demonstrated a favorable safety profile, with only low-grade Cytokine Release Syndrome observed. These findings suggest strong potential for CAR-T therapies in treating solid tumors, marking a significant advancement in Poseida's clinical development.
Poseida Therapeutics (Nasdaq: PSTX) reported significant program advancements and financial results for Q2 2021. Key updates include progressing the P-BCMA-101 trial for multiple myeloma and initiating plans for P-BCMA-ALLO1 and P-MUC1C-ALLO1 IND filings. R&D expenses surged to $36 million, up from $25 million a year earlier, while net losses reached $45.7 million for the quarter. Despite increased expenses, cash reserves stood at $237.3 million as of June 30, 2021, providing a solid buffer for ongoing development. Upcoming data presentation on P-PSMA-101 is scheduled for August 31, 2021.
Poseida Therapeutics (PSTX) has announced the appointment of Cynthia Collins to its Board of Directors, effective July 23, 2021. Collins brings over 40 years of experience in biotechnology, including roles as CEO at Editas Medicine and Human Longevity. Her expertise in gene engineering and oncology is expected to enhance Poseida's development of cell and gene therapies. CEO Eric Ostertag highlighted her valuable contribution as the company advances its proprietary genetic engineering platforms for therapeutic applications.
Poseida Therapeutics, Inc. (Nasdaq: PSTX) announced its virtual Annual Meeting of Stockholders on June 16, 2021, at 1:00pm PT. Stockholders of record as of April 20, 2021, are eligible to vote. An online portal will be available for stockholders to access proxy materials, vote, and submit questions before the meeting. Registration for the meeting must be completed by June 14, 2021, at 8:00pm PT. Poseida Therapeutics emphasizes the importance of advance voting, regardless of attendance at the virtual meeting.
Poseida Therapeutics (PSTX) reported its Q1 2021 progress, highlighting advancements in CAR-T programs and ongoing development of allogeneic therapies. CEO Eric Ostertag noted promising initial results for P-PSMA-101 in prostate cancer treatment. The BCMA-related programs are progressing towards IND filings, although delays due to manufacturing issues were mentioned. Financially, R&D expenses rose to $29.1 million, while net loss widened to $38.3 million. As of March 31, 2021, the company maintained a robust cash position of $270 million.
Poseida Therapeutics (PSTX) presented promising preclinical data on its gene therapies at the American Society of Gene and Cell Therapy 2021 Virtual Annual Meeting. Key highlights include:
- Oral presentation focusing on the piggyBac DNA Delivery System for treating genetic liver disorders in children.
- Two poster presentations on P-BCMA-ALLO1, targeting relapsed/refractory multiple myeloma, showing potent anti-tumor activity.
- Anti-c-kit CAR-T program data suggesting safer options for stem cell transplantation in AML patients.
These advancements reflect Poseida's commitment to innovative treatments in oncology and genetic disorders.
FAQ
What is the current stock price of Poseida Therapeutics (PSTX)?
What is the market cap of Poseida Therapeutics (PSTX)?
What is Poseida Therapeutics, Inc.?
What are Poseida's core technologies?
What is P-BCMA-ALLO1?
Who are Poseida's strategic partners?
What diseases is Poseida targeting with its gene therapies?
What recent financial achievements has Poseida reported?
What is Poseida's approach to gene editing?
How can I learn more about Poseida Therapeutics?
What is the significance of the Orphan Drug Designation for P-BCMA-ALLO1?
What are Poseida's future plans?
